AR053090A1 - Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos - Google Patents
Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentosInfo
- Publication number
- AR053090A1 AR053090A1 ARP050102978A ARP050102978A AR053090A1 AR 053090 A1 AR053090 A1 AR 053090A1 AR P050102978 A ARP050102978 A AR P050102978A AR P050102978 A ARP050102978 A AR P050102978A AR 053090 A1 AR053090 A1 AR 053090A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- cycloalkenyl
- cycloalkyl
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 23
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 15
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 7
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000005541 phosphonamide group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 108091008646 testicular receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
Abstract
Compuesto de formula 1 y sales aceptables para uso farmacéutico de los mismos. Estos compuestos inhiben la enzima IGF-1R y son utiles para el tratamiento y/o prevencion de varias enfermedades y afecciones, que responden al tratamiento por inhibicion de tirosina quinasas, tales como el cancer Rivindicacion 1: Un compuesto representado por la formula 1 o una sal aceptable para uso farmacéutico del mismo, donde Q1 es arilo 1, heteroarilo1, ciclaolaquilo C3-10, heterocicililo, cicloalquenilo C3-10 o heterocicloalquenilo, cualquiera de los cuales se sustituye opcionalmente por uno a cinco sustituyentes independientes G10, R1 es alquilo C0-10, cicloalquilo C3-10, biciclo-alquilo C5-10, arilo, heteroarilo, aralquilo, heteroaralquilo, heterociclo o heterobiciclo-alquilo C5-10, cualquiera de los cuales se sustituye opcionalmente con uno o más sustituyentes independientes G11; G10 y G11 son cada uno independientemente halo, oxo, -CF3, -OCF3, -OR2, -NR2R3(R2a)j1, -C(O)R2, -CO2R2, -CONR2R3, -NO2, -S(O)j1R2, -SO2NR2R3, -NR2C(=O)R3, -NR2C(=O)NR3R2a, -NR2S(O)j1R3, -C(=S)OR2, -C(=O)SR2, -NR2C(=NR3)NR2aR3a, -NR2C(=NR3)OR2a, , NR2C(=NR3)SR2a, -OC(=O)OR2, -OC(=O)NR2R3, -OC(=O)OR2, -CO(=O)NR2R3, alquilo C0-10, alquenilo C2-10, alquinilo C2-10, alcoxi C1-10-alquilo C1-10, alcoxi C1-10-alquenilo C2-10, alcoxi C1-10-alquinilo C2-10, alquitio C1-10-alquilo C1-10, alquiltio C1-10-alquenilo C2-10, alquiltio C1-10-alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalquil C3-8-alquilo C1-10, cicloalquenil C3-8-alquilo C1-10, cicloalquil C3-8-alquenilo C2-10. cicloalquenil C3-8-alquenilo C2-10, cicloalquil C3-8-alquinilo C2-10, cicloalquenil C3-8-alquinilo C2-10, heterociclil-alquilo C0-10, heterociclil-alquenilo C2-10 o heterociclil-alquinilo C2-10, cualquiera de los cuales se sustituy opcionalmente con uno o mássustituyentes independientes halo, oxo, -CF3, -OCF3, -OR222, -NR222R333(R222a)j1a, -C(O)R222, -CO2R222, - CONR222R333, -NO2, -CN, S-(O)j1aR222, -SO2NR222R333, -NR222C(=O)R333, -NR222C(=O)OR333, -R222C(=O)NR333R222a, -NR222S(O)j1aR333, -C(=S)OR222, -C(=O)SR222, -NR222C(=NR333)NR222R333a, -NR222C(=NR333)OR222a, -NR222C(=NR333)SR222a, -OC(=O)OR222, - OC(=)NR222R333, -OC(=O)OR222, -OC(=O)NR222R333, -OC(=O)SR222, -SC(=O)OR222 o -SC(=O)NR222R333; o G10 es opcionalmente -(X1)n-(Y1)m-R4; O G41 es opcionalmente -(X1)n-(Y1)m-alquilo C0-10; o G10 y G41 son cada uno opcionalmente de manera independiente arilalquilo C0-10, arilalquenilo C2-10, arilalquinilo C2-10, hetarilalquilo C0-10, hetarilalquenilo C2-10 o hetarilalquinilo C2-10, cualquiera de los cuales se sustituye opcionalmente con uno o más sustituyentes independientes halo,-CF3, -OCF3, - OR222, -NR222R333(R222a)j1a, -C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN, S-(O)j1aR222, -SO2NR222R333, -NR222C(=O)R333, -NR222C(=O)OR333, -R222C(=O)NR333R222a, -NR222S(O)j1aR333, -C(=S)OR222, -C(=O)SR222, -NR222C(=NR333)NR222R333a, - NR222C(=NR333)OR222a, -NR222C(=NR333)SR222a, -OC(=O)OR222, -OC(=)NR222R333, -OC(=O)OR222, -OC(=O)NR222R333, -OC(=O)SR222, -SC(=O)OR222 o -SC(=O)NR222R333; G11 es halo, oxo, -CF3, -OCF3, -OR21, -NR21R31(R21a)j3, -C(O)R21, -CO2R21, .CONR21R31, -NO2, - CN, -S(O)j3R21, -SO2NR21R31, -NR21C(=O)R31, -NR21C(=O)OR31, -NR21C(=O)NR31R21a, -NR21S(O)j3R31, -C(=S)OR21, -C(=S)OR21, -C(=O)SR21, -NR21C(=NR31)NR21aR31a, -NR21C(=NR31)OR21a, -NR21C(=NR31)SR21a, OC(=O)OR21, -OC(=O)NR21R31, -OC(=O)SR21, - SC(=O)OR21, -SC(=O)NR21R31, -P(O)OR21OR31, alquilo C0-10, alquenilo C2-10, alquinilo C2-10, alcoxi C1-10-alquilo C1-10, alcoxi C1-10-alquenilo C2-10, alcoxi C1-10, alquiltio C1-10-alquilo C1-10, alquiltio C1-10-alquenilo C2-10, alquiltio C1-10- alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalquil C3-8-alquilo C1-10, cicloalquenil C3-8-alquilo C1-10, cicloalquil C3-8-alquenilo C3-8-alquenilo C2-10, cicloalquenil C3-8-alquenilo C2-10, cicloalquil C3-8-alquinilo C2-10, cicloalquenil C3-8-alquinilo C2-10, heterociclil-alquilo C0-10, heterociclil-alquenilo C2-10 o heterociclil-alquinilo C2-10, cualquiera de los cuales se sustituye opcionalmente con uno o más sustituyentes independientes halo, oxo, -CF3, -OCF3, - OR2221, -NR2221R3331(R2221a)j3a, -C(O)R2221, -CO2R2221, -CONR2221R3331, NO2, -CN, -S(O)j3aR2221, SO2NR2221R3331, -NR2221C(=O)R3331, -NR2221C(=O)OR3331, -NR2221C(=O)NR3331R2221a, -NR2221S(O)j3aR3331, -C(=S)OR2221, -C(=O)SR2221, - NR2221C(=NR3331)NR2221aR3331a, -NR2221C(=NR3331)OR2221a, -NR2221C(=NR3331)SR2221a, -OC(=O)OR2221, -OC(=O)NR2221R3331, -OC(=O)SR2221, -SC(=O)OR2221, -P(O)OR2221OR3331 o -SC(=O)NR2221R3331; o G11 es arilalquilo C0-10, arilalquenilo C2-10, o G11 es arilalquilo C0-10, arilalquenilo C2-10, arilalquinilo C2-10, hetarilalquilo C0-10, hetarilalquenilo C2-10 o hetarilalquinilo C2-10, cualquiera de los cuales se sustituye opcionalmente con uno o más hetarilalquinilo C2-10, cualquiera de los cuales se sustituye opcionalmente con uno o más sustituyentes independientes halo, -CF3, -OCF3, -OR2221, -NR2221R3331(R2221a)j3a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j3aR2221, -SO2NR2221R3331, -NR2221C(=O)R3331, -NR2221C(=O)OR3331, - NR2221C(=O)NR3331R2221a, -NR2221S(O)j3aR3331, -C(=S)OR2221, -C(=O)SR2221, -NR2221C(=NR3331)NR2221aR3331a, -NR2221C(=NR3331)OR2221a, -NR2221C(=NR3331)SR2221a, -OC(=O)OR2221, -OC(=O)NR2221R3331, -OC(=O)SR2221, -SC(=O)OR2221, -P(O)OR2221OR3331 o - SC(=O)NR2221R3331; o G11 es C, tomado junto con el carbono al cual se encuentra unido forma un doble enlace C=C que se sustituye con R5 y G12, R2, R2a, R3, R3a, R222, Rrrr1, R333, R333a, R21, R21a, R31, R31a, R2221, R2221a, R3331 y R3331a son cada uno independientemente alquilo C0-10, alquenilo C2-10, alquinilo C2-10, alcoxi C1-10-alquilo C1-10, alquilo C1-10-alquenilo C2-10, alcoxi C1-10-alquinilo C2-10, alquiltio C1-10-alquilo C1-10, alquiltio C1-10-alquenilo C2-10, alquiltio C1-10- alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalquil C3-8-alquilo C1-10, cicloalquenil C3-8-alquilo C1-10, cicloalquil C3-8-alquenilo C2-10, cicloalquenil C3-8-alquenilo C2-10, cicloalquil C3-8-alquinilo C2-10, cicloalquenil C3-8- alquinilo C2-10, heterociclil-alquilo C0-10, heterociclil-alquenilo C2-10, heterociclil-alquinilo C2-10, arilalquilo C0-10, arilalquenilo C2-10, arilalquinilo C2-10, hetarilalquenilo C2-10 o hetarialquinilo C2-10, cualquiera de los cuales se sustituye opcionalmente con uno o más sustituyentes independientes G13 o en el caso de -NR2R3(R2a)j1 o -NR21R31(R21a)j3 o -NR222R333(R222a)j1a o -NR222R333(R222a)j2a o -NR2221R3331(R2221a)j3a, R2 y R3 o R21 y R31 o R222 y R333 o R2221 y R3331, respectivamente, se toman opcionalmente junto con el átomo de nitrogeno al cual se encuentran unidos para formar un anillo saturado o no saturado de 3-10 miembros, donde dicho anillo se sustituye opcionalmente con uno o más sustituyentes independientes G14 y donde dicho anillo incluye opcionalmente uno o más heteroátomos independientes distintos de nitrogeno a los cuales R2 y R3 o R222 y R333 o R2221 y R3331 se encuentran unidos; X1 e Y1 son cada uno independientemente -O-, -NR7-, - S(O)j4-, -CR5R6-, -N(C(O)OR7), -N(C(O)R7)-, -N(SO2R7)-, -CH2O-, -CH2S-, -CH2H(R7)-, -CH(NR7)-, -CH2N(C(O)R7)-, -CH2N(C(O)OR7)-, -CH2N(SO2R7)-, -CH(NHR7)-, -CH(NHC(O)R7)-, -CH(NHSO2R7)-, -CH(NHC(O)OR7)-, -CH(OC(O)R7-, -CH(OC(O)NHR7)-, -CH=CH-, -C:::C- , -C(=NOR7)-, -C(O)-, -CH(OR7)-, -C(O)N(R7)-, -N(R7)C(O)-, -N(R7)S(O)-, -N(R7)S(O)2-OC(O)N(R7)-, -N(R7)C(O)N(R8)-, -NR7C(O)-O-, -S(O)N(R7)-, -S(O)2N(R7)-, -N(C(O)R7S(O)-, -N(C(O)R7)S(O)2-, -N(R7)S(O)N(R8)-, -N(R7)S(O)2N(R8)-, -C(O)N(R7)C(O)-, - S(O)N(R7)C(O)-, -S(O)2N(R7)C(O)-, -OS(O)N(R7)-, -OS(O)2N(R7)-, -N(R7)S(O)-O-, -N(R7)S(O)2-O-, -N(R7)S(O)C(O)-, -N(R7)S(O)2C(O)-, -SON(C(O)R7)-, -SO2N(C(O)R7)-, -N(R7)SON(R8)-, -(R7)SO2N(R8)-, -N(R7)SO2N(R8)-, -C(O)-O-, N(R7)P(OR8)-O-, -N(R7)P(OR8)- , -N(R7)P(O)(OR8)-O-, -N(R7)P(O)(OR8)-, N(C(O)R7)P(OR8)-O-, -N(C(O)R7)P(OR8)-, -N(C(O)R7)P(O)(OR8)-O-, -N(C(O)R7)P(OR8)-, -CH(R7)S(O)-, -CH(R7)S(O)2, --CH(R7)N(C(O)OR8)-, -CH(R7)N(C(O)R8)-, -CH(R7)N(SO2R8)-, -CH(R7)-O-. --CH(R7)S-, CH(R7)N(R8)-, - CH(R7)N(C(O)R8)-, -CH(R7)N(C(O)OR8)-, -CH(R7)N(SO2R8)-, -CH(R7)C(=NOR8)-, -CH(R7)C(O)-, -CH(R7)CH(OR8)-, -CH(R7)C(O)N(R8)-, -CH(R7)N(R8)C(O)-, -CH(R7)N(R8)S(O)-, -CH(R7)N(R8)S(O)2-, -CH(R7)OC(O)N(R8)-, -CH(R7)N(R8)C(O)N(R7a)-, -CH(R7)NR8C(O)-O-, - CH(R7)S(O)N(R8)-, -CH(R7)S(O)2N(R8)-, -CH(R7)N(C(O)R8)S(O)-, -CH(R7)N(C(O)R8)S(O)-, -CH(R7)N(R8)S(O)N(R7a)-, -CH(R7)N(R8)S(O)2N(R7a)-, -CH(R7)C(O)N(R8)C(O)-, -CH(R7)S(O)N(R8)C(O)-, -CH(R7)S(O)2N(R8)C(O)-, -CH(R7)OS(O)N(R8)-, -CH(R7)OS(O)2N(R8)-, - CH(R7)N(R8)S(O)-O-, -CH(R7)N(R8)S(O)2-O-, -CH)R7)N(R8)S(O)C(O)-, -CH(R7)N(R8)S(O)2C(O)-, -CH(R7)SON(C(O)R8)-, -CH(R7)SO2N(C(O)R8)-, -CH(R7)N(R8)SON(R7a)-, -CH(R7)N(R8)SO2N(R7Aa)-, -CH(R7)C(O)-O-, -CH(R7)N(R8)P(OR7a)-O-, -CH(R7)N(R8)P(OR7a)-, - CH(R7)N(R8)P(O)(OR7a)-O-, -CH(R7)N(R8)P(O)(OR7a)-, -CH(R7)N(C(O)R8)P(OR7a)-O-, -CH(R7)N(O)R8)P(OR7a)-, -CH(R7)N(C(O)R8)P(O)OR7a)-O- o -CH(R7)N(C(O)R8)P(OR7a)-; o X1 e Y1 se representan cada uno independientemente por una de las siguientes formulas estructurales: 1, 2, 3, 4, 5 0 6, R10 tomado junto con la fosfinamida o fosfonamida, forman un sistema anular arilo, heteroarilo o heterociclilo de 5, 6 o 7 miembros; R5, R6, G12, G13, G14 y G15 son cada uno independientemente alquilo C0- 10, alquenilo C2-10, alquinilo C2-10, alcoxi C1-10-alquilo C1-10, alcoxi C1-10-alquenilo C2-10, alcoxi C1-10-alquinilo C2-10, alquiltio C1-10-alquilo C1-10, alquiltio C1-10-alquenilo C2-10, alquiltio C1-10-alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalquil C3-8-alquilo C1-10, cicloalquenil C3-8-alquilo C1-10, cicloalquil C3-8-alquenilo C2-10, cicloalquenil C3-8-alquenilo C2-10, cicloalquil C3-8-alquinilo C2-10, cicloalquenil C3-8-alquinilo C2-10, hererociclil-alquilo C0-10, heterociclil-alquenilo C2-10, heterociclil-alquinilo C2-10, aralquilo C0-10, arilalquenilo C2-10, arilalquinilo C2-10, hetarilalquilo C0-10, hetarilalquenilo C2-10 o hetarilalquenilo C2-10 o hetarilalquinilo C2-10, cualquiera de
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58951404P | 2004-07-20 | 2004-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR053090A1 true AR053090A1 (es) | 2007-04-25 |
Family
ID=35482337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102978A AR053090A1 (es) | 2004-07-20 | 2005-07-19 | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
Country Status (18)
Country | Link |
---|---|
US (1) | US7741324B2 (es) |
EP (1) | EP1781660A1 (es) |
JP (1) | JP4918038B2 (es) |
KR (1) | KR20070035087A (es) |
CN (1) | CN101084218A (es) |
AP (1) | AP2007003924A0 (es) |
AR (1) | AR053090A1 (es) |
AU (1) | AU2005267120B2 (es) |
BR (1) | BRPI0513565A (es) |
CA (1) | CA2574594A1 (es) |
EA (1) | EA200700220A1 (es) |
IL (1) | IL180806A0 (es) |
MX (1) | MX2007000822A (es) |
MY (1) | MY139689A (es) |
NO (1) | NO20070917L (es) |
RU (1) | RU2007106068A (es) |
TW (1) | TW200613306A (es) |
WO (1) | WO2006012422A1 (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
EP2168968B1 (en) | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
EP1951724B1 (en) * | 2005-11-17 | 2011-04-27 | OSI Pharmaceuticals, Inc. | FUSED BICYCLIC mTOR INHIBITORS |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
WO2007087395A2 (en) * | 2006-01-25 | 2007-08-02 | Osi Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
AU2007323725B2 (en) | 2006-11-22 | 2014-02-20 | Incyte Holdings Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
SG10201508035TA (en) * | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
EP2463679B1 (en) * | 2007-05-01 | 2020-03-11 | Qualcomm Incorporated(1/3) | Position location for wireless communication systems |
US8130700B2 (en) | 2007-06-15 | 2012-03-06 | Silver Spring Networks, Inc. | Method and system for providing network and routing protocols for utility services |
WO2009091939A1 (en) * | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
EP2276763A1 (en) * | 2008-03-19 | 2011-01-26 | OSI Pharmaceuticals, Inc. | Mtor inhibitor salt forms |
JP2011520970A (ja) * | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
MY187131A (en) * | 2008-05-21 | 2021-09-02 | Incyte Corp | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
DE102009005193A1 (de) * | 2009-01-20 | 2010-07-22 | Merck Patent Gmbh | Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren |
CN102405214A (zh) | 2009-04-20 | 2012-04-04 | Osi药物有限责任公司 | C-吡嗪-甲胺的制备 |
EP2427192A1 (en) * | 2009-05-07 | 2012-03-14 | OSI Pharmaceuticals, LLC | Use of osi-906 for treating adrenocortical carcinoma |
US8487096B2 (en) * | 2010-02-03 | 2013-07-16 | Incyte Corporation | Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors |
EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
EA031737B1 (ru) | 2010-06-03 | 2019-02-28 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы |
WO2012106556A2 (en) | 2011-02-02 | 2012-08-09 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
JP5543039B2 (ja) * | 2011-02-23 | 2014-07-09 | ファイザー・インク | 神経障害治療のためのイミダゾ[5,1−f][1,2,4]トリアジン |
JP2014520863A (ja) | 2011-07-13 | 2014-08-25 | ファーマサイクリックス,インク. | Bruton型チロシンキナーゼの阻害剤 |
US9700619B2 (en) | 2011-11-11 | 2017-07-11 | Duke University | Combination drug therapy for the treatment of solid tumors |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
SG11201403909RA (en) | 2012-01-26 | 2014-10-30 | Lundbeck & Co As H | Pde9 inhibitors with imidazo triazinone backbone |
CN103374001B (zh) * | 2012-04-19 | 2015-10-28 | 山东轩竹医药科技有限公司 | 咪唑并三嗪类mTOR抑制剂 |
CA2875986C (en) | 2012-06-04 | 2020-06-09 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
WO2014018567A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
EP2920180A4 (en) | 2012-11-15 | 2016-04-13 | Pharmacyclics Inc | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS |
CA2925124A1 (en) | 2013-09-30 | 2015-04-02 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
CA2922058A1 (en) * | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
WO2015081783A1 (zh) * | 2013-12-06 | 2015-06-11 | 江苏奥赛康药业股份有限公司 | 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途 |
EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
CA2959602A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
MD3265084T2 (ro) | 2015-03-03 | 2024-05-31 | Pharmacyclics Llc | Formulări farmaceutice ale inhibitorului tirozin kinazei Bruton |
AU2016289856B2 (en) | 2015-07-07 | 2020-11-26 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
PE20190175A1 (es) * | 2016-03-28 | 2019-02-01 | Incyte Corp | Compuestos de pirrolotriazina como inhibidores de tam |
EP3548046A2 (en) * | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
KR20200088308A (ko) | 2017-09-27 | 2020-07-22 | 인사이트 코포레이션 | Tam 억제제로서 유용한 피롤로트리아진 유도체의 염 |
SI3801526T1 (sl) | 2018-05-25 | 2024-05-31 | Cardurion Pharmaceuticals, Inc. | Monohidratne in kristalinične oblike 6-((3s, 4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il)-3-tetrahidropiran-4- il-7h-imidazo (1.5 - a) pirazin-8-ona |
AR117600A1 (es) | 2018-06-29 | 2021-08-18 | Incyte Corp | Formulaciones de un inhibidor de axl / mer |
WO2023196975A1 (en) * | 2022-04-08 | 2023-10-12 | Shy Therapeutics, Llc | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
ATE114661T1 (de) | 1990-04-02 | 1994-12-15 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
JPH06503095A (ja) | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
MX9304801A (es) | 1992-08-06 | 1997-06-28 | Warner Lambert Co | 2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales. |
JPH08503450A (ja) | 1992-08-06 | 1996-04-16 | ワーナー−ランバート・コンパニー | 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する2−チオインドール(セレノインドール)および関連ジスルフィド(セレニド) |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
JPH07133280A (ja) | 1993-11-09 | 1995-05-23 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
US5584409A (en) * | 1995-09-18 | 1996-12-17 | Chemberlen; Christopher H. | One direction ventilation valves |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
NZ332645A (en) | 1996-05-01 | 2000-07-28 | Lilly Co Eli | use of a bis-indolylmaleimide derivative for treating VEGF related diseases |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
UA54427C2 (uk) | 1996-05-01 | 2003-03-17 | Елі Ліллі Енд Компані | Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
NZ510588A (en) | 1998-09-18 | 2003-08-29 | Abbott Gmbh & Co | Pyrrolopyrimidines as protein kinase inhibitors |
US6337338B1 (en) | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
CA2373990C (en) | 1999-05-21 | 2007-05-08 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
AU2000240570A1 (en) * | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
JP3933420B2 (ja) * | 2001-07-24 | 2007-06-20 | 出光ユニテック株式会社 | 収納袋の排気弁 |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
GB0122560D0 (en) | 2001-09-19 | 2001-11-07 | Aventis Pharma Ltd | Chemical compounds |
MXPA04002243A (es) | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
US6827492B2 (en) * | 2001-12-05 | 2004-12-07 | Leland B. Cook | One-way concealed-valve vented storage bag |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
CA2476000A1 (en) | 2002-02-14 | 2003-08-21 | Dana-Farber Cancer Institute Inc. | Methods and compositions for treating hyperproliferative conditions |
US20050215564A1 (en) | 2002-02-14 | 2005-09-29 | Stiles Charles D | Methods and compositions for treating hyperproliferative conditions |
DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
MXPA05009660A (es) | 2003-03-12 | 2005-10-20 | Pfizer Prod Inc | Derivados azabiciclicos de piridiloximetilo y bencisoxazol. |
EP2168968B1 (en) * | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
-
2005
- 2005-07-19 TW TW094124340A patent/TW200613306A/zh unknown
- 2005-07-19 MY MYPI20053287A patent/MY139689A/en unknown
- 2005-07-19 AR ARP050102978A patent/AR053090A1/es not_active Application Discontinuation
- 2005-07-20 EA EA200700220A patent/EA200700220A1/ru unknown
- 2005-07-20 EP EP05773226A patent/EP1781660A1/en not_active Withdrawn
- 2005-07-20 WO PCT/US2005/025891 patent/WO2006012422A1/en active Application Filing
- 2005-07-20 AP AP2007003924A patent/AP2007003924A0/xx unknown
- 2005-07-20 KR KR1020077003827A patent/KR20070035087A/ko not_active Application Discontinuation
- 2005-07-20 BR BRPI0513565-6A patent/BRPI0513565A/pt not_active IP Right Cessation
- 2005-07-20 AU AU2005267120A patent/AU2005267120B2/en not_active Ceased
- 2005-07-20 MX MX2007000822A patent/MX2007000822A/es active IP Right Grant
- 2005-07-20 CN CNA2005800317167A patent/CN101084218A/zh active Pending
- 2005-07-20 CA CA002574594A patent/CA2574594A1/en not_active Abandoned
- 2005-07-20 JP JP2007522756A patent/JP4918038B2/ja not_active Expired - Fee Related
- 2005-07-20 RU RU2007106068/04A patent/RU2007106068A/ru not_active Application Discontinuation
- 2005-07-20 US US11/185,599 patent/US7741324B2/en not_active Expired - Fee Related
-
2007
- 2007-01-18 IL IL180806A patent/IL180806A0/en unknown
- 2007-02-16 NO NO20070917A patent/NO20070917L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2005267120A1 (en) | 2006-02-02 |
TW200613306A (en) | 2006-05-01 |
US20060019957A1 (en) | 2006-01-26 |
EP1781660A1 (en) | 2007-05-09 |
JP2008507546A (ja) | 2008-03-13 |
MY139689A (en) | 2009-10-30 |
IL180806A0 (en) | 2007-06-03 |
NO20070917L (no) | 2007-03-19 |
RU2007106068A (ru) | 2008-08-27 |
EA200700220A1 (ru) | 2007-08-31 |
CA2574594A1 (en) | 2006-02-02 |
BRPI0513565A (pt) | 2008-05-06 |
JP4918038B2 (ja) | 2012-04-18 |
KR20070035087A (ko) | 2007-03-29 |
MX2007000822A (es) | 2007-04-02 |
CN101084218A (zh) | 2007-12-05 |
AU2005267120B2 (en) | 2011-06-02 |
WO2006012422A1 (en) | 2006-02-02 |
AP2007003924A0 (en) | 2007-02-28 |
US7741324B2 (en) | 2010-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR053090A1 (es) | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos | |
AR048518A1 (es) | Inhibidores heterobiciclicos de proteina quinasas sustituidos con anillos 6,6 -biciclicos | |
CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
CY1118842T1 (el) | Αναισθητικες ενωσεις και σχετιζομενες μεθοδοι χρησεις | |
MA42232B1 (fr) | Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant | |
NI201200172A (es) | Activadores de guanilato ciclasa soluble | |
AR085039A1 (es) | DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR | |
CY1117085T1 (el) | C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης | |
AR074826A1 (es) | Regimen de dosificacion para un agonista de los receptores de s1p | |
ECSP12011610A (es) | Inhibidores de la replicación de los virus de la gripe | |
PA8635201A1 (es) | Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos | |
MX2020004283A (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
RU2012153164A (ru) | Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути | |
CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
AR086086A1 (es) | Derivados glucosidos y usos de los mismos | |
AR093408A1 (es) | Derivados de oxazolidin-2-ona-pirimidina | |
AR087868A1 (es) | Compuestos de triazolopiridina como moduladores de la tirosina quinasa c-met | |
BR112015028760A2 (pt) | compostos para inibição de cepas de integrase do hiv-1 resistentes a drogas | |
BR112016013618A8 (pt) | derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos | |
PE20210478A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
CO2021014210A2 (es) | Compuestos de pirrol | |
CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
AR088414A1 (es) | Derivados sustituidos de indol | |
AR087346A1 (es) | Formulaciones de compuestos de tiofeno | |
AR119317A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |